Citalopram vs Clomipramine vs Placebo in Recurrent Depression

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01575158

Enrollment

Registered

2012-04-11

Start date

1997-10-31

Completion date

2007-09-30

Last updated

2012-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

citalopram and clomipramine are better than placebo in preventing new episodes of depression in patients with recurrent depression

Interventions

DRUGCitalopram

DRUGClomipramine

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients with recurrent depression * Sustained response achieved (3 consecutive monthly ratings at the HDS below 13)after a treatment requiring index episode

Exclusion criteria

* Contraindications to study medications * Pregnancy * Substance abuse

Design outcomes

Primary

Measure	Time frame
2 Hamilton Depression Rating Scale scores of at least 16 with one weeks interval or initiation of another antidepressant treatment	2 years of follow-up

Secondary

Measure	Time frame
Study termination due to adverse event or non-compliance	2 years of follow-up

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026